Global risk management in type 2 diabetes: Blood glucose, blood pressure, and lipids - Update on the background of the current guidelines

Experimental and Clinical Endocrinology and Diabetes

Volumn 112, Issue 9, 2004, Pages 493-503

  Clemens, Andreas ^a   Siegel, E ^b   Gallwitz, B ^c  

^a St Vincenz Krankenhaus ^*  (Germany)

^b St Vincenz Krankenhaus   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cardiovascular risk management; Diabetes guidelines; Dyslipidemia; Hypertension; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN ASPART; INSULIN LISPRO; INSULIN SENSITIZING AGENT; LIPID; LONG ACTING DRUG; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; RESIN; SULFONYLUREA DERIVATIVE;

ANTICOAGULANT THERAPY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COMORBIDITY; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK MANAGEMENT; SMOKING CESSATION;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; LIPIDS;

EID: 7644237238     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-821306     Document Type: Review

References (97)

1. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419
2. Alberti G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998-1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes 1999; 107: 390-420
3. Alvarsson M, Steen L, Sundkvist G, Westermark G, Lager I, Westermark P, Henricsson M, Örn T, Berntrop K, Grill V, Fernquist-Forbes E. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabet Care 2003; 26: 2231-2237
4. American Diabetes Association. Aspirin therapy in diabetes (Position statement). Diabet Care 2003; 26: S87-S88
5. American Diabetes Association. Aspirin therapy in diabetes. Diabet Care 2000; 23: S61-S62
6. American Diabetes Association. Diabetes management in correctional institutions. Diabet Care 2004a; 27: S114-S121
7. American Diabetes Association. Hypertension management in adults with diabetes. Diabet Care 2004 b; 27: S65-S67
8. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabet Care 2002; 25: S74-S77
9. Armitage J. Lipid-lowering trails in diabetes. Eur Heart J 1999; 1: M13-M17
10. Arauz-Pacheco C, Parrot MA. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25:134-147
11. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. Ann Intern Med 1999; 131:182-188
12. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661
13. Brand FN, Kannel WB, Evans J, Larson MG, Wolf PA. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study. Am Heart J 1998; 136: 919-927
14. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabet Care 2003; 26: 1796-1801
15. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L. World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee. Clin Exp Hypertens 1999; 21: 1009-1060
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Programm Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289: 2560-2572
17. Corpus RA, George PB, House JA, Dixon SR, Ajulin SC, Devlin WH, Timmis GC, Balasubramaniam M, O'Neill WW. Optimal glycemic control is associated with lower rate of target vessel revascularisation in treated type II diabetic patients undergoing elective percutaneous coronary intervention.J Am Coll Cardiol 2004; 43: 8-14
18. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892
19. Deutsche Hochdruckliga, Deutsche Hypertonie Gesellschaft. Empfehlungen zur Hochdruckbehandlung. 16th ed. Heidelberg: Deutsche Hochdruckliga, 2001
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
21. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Ateroscler Thromb 1992; 12: 1496-1502
22. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabet Care 2003; 26: 2777-2784
23. Fonseca V, Rosenstock J, Patwardhan, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized, controlled trail. J Am Med Assoc 2000; 283: 1695-1702
24. Fuller JH, Head J. Blood pressure, proteinuria and their relationship with circulatory mortality: the WHO multinational study of vascular disease in diabetics. Diabetes Metab 1998; 15: 273-277
25. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
26. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterinemia. Am J Cardiol 2002; 90: 1084-1091
27. Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterinemia. Diabetes Obesity Metabol 2000; 2: 355-362
28. Gohlke H, Kübler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G. Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 2001; 90: 148-149
29. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-2519
30. Greco AV, Mingrone G, Giancaterini A, Manco M, Morroni M, Cint S, Granzotto M, Vettor R, Camastra S, Ferrannini E. Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144-151
31. Guidelines Committee. 2003 European society of hypertension - european society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
32. Haffner SM, Hanley AJG. Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation 2002; 105: 2008-2009
33. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. Implications for treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
34. Haller H. Posprandial glucose and vascular disease. Diabetic Medicine 1997; 14: S50-S56
35. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabet Care 1991; 14: 308-317
36. Hanefeld M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabetic Medicine 1999; 16: 212-218
37. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT). HOT Study Group. Lancet 1998; 351: 1755-1762
38. Häring H-U, Joost H-G, Laube H, Matthaei S, Meissner H-P, Panten U, Schernthaner G. Evidenzbasierte Diabetes-Leitlinien DDG (Diskussionsentwurf). Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetes und Stoffwechsel 2001; 10: 223-236
39. Hauner H, Köster I, von Ferber L. Prävalenz des Diabetes mellitus in Deutschland 1998-2001. Dtsch Med Wochenschr 2003; 128: 2632-2638
40. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
42. Heinemann L, Heise T. Klinische Wirkungen und Pharmakodynamik der Insulinanaloga Lispro, Aspart und Glargin. Dtsch Med Wschr 2001; 126: 597-604
43. Hermann LS, Ranstam J, Vaaler, Melander A. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab 1999; 1: 227-232
44. Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS. Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diab Int 2003; 20: 63-71
45. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325
46. Janka HU, Standl E, Bloss G, Oberparleiter F, Mehnert H. On the epidemiology of hypertension in diabetics. Dtsch Med Wochenschr 1978; 103: 84-87
47. Jarrett RJ, Shipley MJ. The Whitehall Study: comparative mortality rates and indices of risk in diabetes. Acta Endocrinol 1985; 110: 21-26
48. Jeu LA, Cheng JWM. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003; 25: 2352-2387
49. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2443
50. Kalfhaus J, Berger M. Insulin treatment with preprandial injections of regular insulin in middle-aged type 2 diabetic patients. A two years observational study. Diabetes & Metabolism 2000; 26: 197-201
51. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors in the framingham study. Circulation 1993; 59: 8-13
52. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Daibetes Care 2003; 26: 2713-2721
53. Klocke KR, Stauch K, Landen H. Effect of add-on acarbose to insulin therapy in routine clinical practice. Clin Drug Invest 2003; 23: 621-627
54. Lefèbvre PJ and Scheen AJ. Glucose metabolism and the postprandial state. Eur J Clin Invest 1999; 29:1-6
55. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part II. Circulation 2003; 108: 1655-1661
56. Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Circulation 1999; 99: 2626-2632
57. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45
58. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884-886
59. Menzel R, Kerner W, Meinecke G, Schmohl M. Typ-2-Diabetes: Insulintherapie kombiniert mit Metformin im Vergleich zur Insulinmonotherapie. Diabetes und Stoffwechsel 2002; 11: 167-174
60. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-75
61. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 676-685
62. Nationales Programm für Versorgungs-Leitlinien bei der Bundesärztekammer. Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2. Mai 2002; Kurzfassung. Diabetes und Stoffwechsel 2002; 11: 185-205
63. Oh J-Y, Barret-Connor E, Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults. Circulation 2002; 105: 1311-1316
64. Parving HH and Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 229: 230-233
65. Practice Guidelines Writing Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1011-1053
66. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S). Diabet Care 1997; 20: 614-620
67. Reaven PD, Barrett-Connor EL, Browner DK. Abnormal glucose tolerance and hypertension. Diabet Care 1990; 13: 119-125
68. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299: 1127-1131
69. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med 2002; 162: 2597-2604
70. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-1009
71. Sawicki PT, Mühlhauser I, Didjurgeit U. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro- or macroproteinuria. Diabet Med 1995; 12: 893-898
72. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 1994; 344: 1383-1389
73. Schäfers RF, Lütkes P, Ritz E, Philipp T. Leitlinie zur Behandlung der arteriellen Hypertonie bei Diabetes mellitus. DMW 1999; 124: 1356-1372
74. Second joint task force of European and other societies on coronary heart disease in clinical practice. Recommendation of the second joint task force of European and other societies on coronary prevention Euro Heart
75. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-1054
76. Shek A, Ferill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917
77. Siegel EG, Jakobs R, Riemann JF. Pankreopriver und hepatogener Diabetes. Internist 2001; 42: S8-S19
78. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabet Care 1988; 11: 821-827
79. Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587-592
80. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabet Care 1993; 16: 434-444
81. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-1545
82. Standl E, Fuchs C, Parandeh-Shab F, Janka UH, Landgraf R, Lengeling H-F, Phillip T, Petzoldt R, Sawicki P, Scherbaum WA, Tschöpe D. Hypertonie beim Diabetes Mellitus. In: Scherbaum WA, Landgraf R (eds). Praxisleitlinien der Deutschen Diabetes-Gesellschaft (DDG). Diabetes und Stoffwechsel 2002; 11: 20-22
83. Standl E, Fuchs C, Parandeh-Shab F, Janka UH, Landgraf R, Lengeling H-F, Phillip T, Petzoldt R, Sawicki P, Scherbaum WA, Tschöpe D. Management der Hypertonie beim Patienten mit Diabetes mellitus. In: Scherbaum WA, Lauterbach KW, Renner R (eds). Evidenzbasierte Diabetes-Leitlinien DDG. 1st ed. Deutsche Diabetes-Gesellschaft, 2000
84. Standl E, Stiegler H, Roth R, Schulz K, Lehmacher W. On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing GP-Program. Diabetes Metab 1989; 15: 352-358
85. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. On behalf of the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type-2-diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
86. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002; 288: 2981-2997
87. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabet Care 2003; 11: 3160-3167
88. Tomigana M, Igarashi K, Eguchi H, Kato T, Manaka H, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabet Care 1999; 22: 920-924
89. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trail investigators. N Engl J Med 1999; 340: 677-684
90. Turner RC. The U. K. prospective diabetes study. A review. Diabet Care 1998; 21: C35-38
91. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
92. Van den Berghe G, Wouters D, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367
93. West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabet Care 1983; 6: 361-369
94. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabet Care 2004; 27: 1047-1054
95. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey Smith G. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly study. Diabetologia 2002; 45: 327-336
96. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C Proinsulin is an independent predictor of coronary heart disease. Circulation 2002; 105: 2153-2158
97. Zimmet PZ, McCarty DJ, De Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997; 11: 60-68